Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Rita Nanda"'
Autor:
Rebecca G. Bagley, Denise A. Yardley, Volker Möbus, Abdel-Baset Halim, Rita Nanda, Gail S. Wright, Andres Forero-Torres, Thomas Hawthorne, Javier Cortes, Alberto J. Montero, Linda T. Vahdat, Kimberly L. Blackwell, Michelle E. Melisko, Melinda L. Telli, Yi He, Peter Schmid, Cynthia X. Ma, Christopher D. Turner
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Scientia
NPJ Breast Cancer
Scientia
NPJ Breast Cancer
Breast cancer; Cancer Càncer de mama; Càncer Cáncer de mama; Cáncer The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negat
Autor:
Nike Beaubier, Gini F. Fleming, Anna Woodard, Padma Sheila Rajagopal, Yonglan Zheng, Galina Khramtsova, Abiola Ibraheem, Elisabeth Sveen, Benjamin D. Leibowitz, Olufunmilayo I. Olopade, Minoru Miyashita, Rita Nanda, Nora Jaskowiak, Kevin P. White, Jean Baptiste Reynier, Joshua S.K. Bell, Toshio F. Yoshimatsu, Dezheng Huo, Fang Liu
Publikováno v:
Cancer Research. 81:SS1-04
Background: Breast cancer demonstrates heterogeneity in biological features, and the therapeutic strategy depends on tumor subtype. African-Ancestry (AA) patients experience a disproportionally high rate of triple negative breast cancer (TNBC) and wo
Autor:
Sherene Loi, Peter Schmid, Javier Cortes, David W. Cescon, Eric P. Winer, Deborah L. Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, Roberto Salgado, Vassiliki Karantza, Petar Jelinic, Anran Wang, Lingkang Huang, Razvan Cristescu, Lakshman Annamalai, Jennifer Yearley, Sylvia Adams
Publikováno v:
Cancer Research. 81:PD14-07
Background: In the phase 2 KEYNOTE-086 study (NCT02447003), pembrolizumab monotherapy had durable antitumor activity in a subset of patients with previously treated mTNBC (cohort A; n = 170) and in patients with previously untreated PD-L1-positive mT
Autor:
Melinda E. Sanders, Yu Shyr, Richard G. Abramson, Jennifer A. Pietenpol, Carlos L. Arteaga, Rita Nanda, Anna Maria Storniolo, Julie R. Nangia, Paula I. Gonzalez-Ericsson, Kimberly N. Johnson, Erica L. Mayer, Brian D. Lehmann, Violeta Sanchez, Antonio C. Wolff, Catherine Van Poznak, Tufia C. Haddad, Vandana G Abramson, Sheau-Chiann Chen
Publikováno v:
Clinical Cancer Research. 26:2111-2123
Purpose: Preclinical data demonstrating androgen receptor (AR)–positive (AR+) triple-negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition catalyzed an investigator-initiated, multi-institutional phase Ib/II study
Autor:
Yen-Shen Lu, Binghe Xu, Chen-En Tsai, Priyanka Sharma, Rita Nanda, Sung-Bae Kim, Louis W.C. Chow, Hope S. Rugo, Peter A. Fasching, Chiun-Sheng Huang, Richard Schwab, Javier Cortes
Publikováno v:
Cancer Research. 80:OT1-08
Background: Adagloxad simolenin (AS) is an investigational immune stimulant comprising the Globo H hexasaccharide epitope linked to the carrier protein keyhole limpet hemocyanin (KLH). KLH facilitates a more vigorous immune response given the weak an
Publikováno v:
Expert Opin Investig Drugs
Introduction Breast cancer has traditionally been viewed as immunogenically 'cold', but two immune checkpoint inhibitors are now approved in combination with chemotherapy for PD-L1 positive advanced triple-negative breast cancer (TNBC), and pembroliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b543f1d47909c960a0e021730ae40778
https://europepmc.org/articles/PMC8995399/
https://europepmc.org/articles/PMC8995399/
Autor:
Rebecca G. Bagley, Cynthia X. Ma, Yi He, J. Cortés, Andres Forero-Torres, V Moebus, Linda T. Vahdat, CD Turner, Abdel Halim, Melinda L. Telli, M. Melisko, Peter Schmid, G Wright, Esther Holgado, Alberto J. Montero, L Fehrenbacher, K. L. Blackwell, D. A. Yardley, Rita Nanda
Publikováno v:
Cancer Research. 79:P6-20
Background gpNMB is an internalizable transmembrane protein overexpressed in ˜40% of TNBC, and associated with a worse prognosis. Preclinical data implicates gpNMB in tumor invasion and metastasis. GV is a novel ADC designed to deliver monomethyl au
Autor:
Phillip M. Garfin, Michaela Tsai, S. Wu, Rita Nanda, J. Abraham, Ian E. Krop, H. Assad, HS Han, Shanu Modi, Monica M. Mita, Huiling Li, Lajos Pusztai, Jennifer M. Specht, A.J. Montero, Sara A. Hurvitz, K. Tkaczuk, D. Medgyesy, Sharon Wilks, H. A. Burris, Joyce O'Shaughnessy
Publikováno v:
Annals of Oncology. 32:S474-S475
Autor:
Rita Nanda, Claudine Isaacs, Bradley A. Hancock, Reshma Mahtani, Carla I. Falkson, Casey Bales, Michael A. Thompson, Kathy D. Miller, Maureen Cooper, Anna Maria Storniolo, Lee A. Albacker, Bryan P. Schneider, Tarah J. Ballinger, Marcelo Blaya, Guanglong Jiang, Yuan Zhong, Milan Radovich, Elisavet Paplomata, Chun Li Chang, Dean Pavlick, Sunil Badve, Erica Cantor, Christopher R. Chitambar, Yu-Hsiang Chen, Robert Graham, Cagri A. Savran, Jeffrey P. Solzak, Karen Daily, Radhika Walling, Christopher Gallagher, Filipa Lynce, Jeffrey P. Gregg, Fei Shen
Publikováno v:
JAMA oncology. 6(9)
Importance A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor ce
Autor:
Iulia Cristina Tudor, Laura García-Estévez, Hirdesh Uppal, Ahmad Awada, Javier Cortes, Ayca Gucalp, Eric P. Winer, Kathy D. Miller, Denise A. Yardley, Rita Nanda, Amy C. Peterson, Tiffany A. Traina, Maureen E. Trudeau, Janice F. Eakle, William J. Gradishar, Peter Schmid, Catherine M. Kelly, Joyce O'Shaughnessy, Joyce Steinberg, Lee S. Schwartzberg
Publikováno v:
Journal of Clinical Oncology. 36:884-890
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of e